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Although the p53 tumor suppressor was identified nearly
three decades ago and plays a pivotal role in human can-
cer, its complexity continues to surprise the research
community. Indeed, it was only recently discovered that
p53 belongs to a multigene family that also includes p63
and p73 (Kaghad et al. 1997; Schmale and Bamberger
1997). Both p63 and p73 express an array of isoforms as a
result of multiple promoter usage and alternative splic-
ing (Yang et al. 1998; Zaika et al. 2002). This complexity
within the p53 gene family has, until now, been consid-
ered a unique feature of p63 and p73. In this issue, Bour-
don et al. (2005) use currently available molecular tech-
niques to revisit the structure of p53, the founding mem-
ber of this gene family. This work reveals that like the
p53-related genes p63 and p73, p53 also makes use of
several promoters and undergoes alternative splicing to
generate multiple isoforms. Thus, a comparison of p53-
related genes reveals strikingly similar traits among fam-
ily members that produce a plethora of related but func-
tionally diverse proteins that add further complexity to
the role of p53-related proteins in development, cancer,
and aging.
Transcriptional initiation, the start of the story
Sequence analysis reveals that p53-like genes in lower
organisms such as the squid are more closely related to
p63 and p73 than they are to p53. Although invertebrates
have a single p53-like gene, mammals are equipped with
three. These findings suggest that p53 is the most recent
member of this gene family that has apparently evolved
in multicellular organisms to cope with the otherwise
dire consequences of DNA damage (Kaghad et al. 1997;
Schmale and Bamberger 1997; Yang et al. 1998). The
structures of p63 and p73 and the notion that the p53
gene family arose from triplication of a more ancestral
gene such as p63 (Yang et al. 1998) provided the impetus
for taking another look at the structure of the p53 gene.
In this issue, David Lane’s group (Bourdon et al. 2005)
describes the characterization of p53 using current mo-
lecular biological techniques. Indeed, when p53 was first
identified by Lane and Crawford (1979) and others as a
protein interacting with the SV40 T-antigen, PCR had
not yet been invented; this technology would not be re-
ported for another seven years (Mullis et al. 1986; Mullis
and Faloona 1987). Using a PCR-based approach, Bour-
don et al. (2005) began by identifying transcriptional
start sites within p53. When primers specific for differ-
ent exons that encode the p53 DNA-binding domain
(DBD) were used to amplify capped p53 transcripts that
are expressed in the normal human colon, five dis-
tinct products were generated (Fig. 1). Sequencing of the
cDNAs that were generated when exon 4 reverse primers
were used revealed that one of the products encoded the
p53 isoform that was described previously (Bienz-
Tadmor et al. 1985; Lamb and Crawford 1986). However,
two different transcripts were found that had different N
termini and arose from distinct transcriptional start sites
separated by 54 nucleotides within noncoding exon 1.
Although both of these transcripts encoded full-length
p53, only the more 3 transcriptional start site had been
described prior to this (Bienz-Tadmor et al. 1985; Lamb
and Crawford 1986). The biological relevance of the
newly discovered start site was not addressed, but it is
interesting to speculate that different upstream activa-
tors of p53 might provide specificity by selectively
modulating these different transcription initiation sites,
thus assuring that diverse stimuli converge to activate
p53 expression. It is possible that the different tran-
scripts have distinct translation efficiencies and/or sta-
bilities. Defining the precise transcriptional start sites
and determining whether this tandem array of transcrip-
tion initiation sites is conserved between species should
help to determine whether the two different p53 tran-
scripts have any biological significance.
When Bourdon et al. (2005) sequenced the cDNAs ob-
tained with primers specific for exon 5, three different
products were generated (Fig. 1). These represented the
two p53 transcripts initiated within exon 1 as described
above, as well as a third cDNA that contained intron 4
sequence at its 5 end, suggesting that this transcript was
generated by a novel promoter located within intron 4.
By assaying different intron 4-specific primers for their
ability to amplify p53 transcripts from total RNA pools
obtained from different human tissues, the relative loca-
tion of a previously unidentified transcriptional start site
within intron 4 was identified. This newly identified
transcript has a single open reading frame that encodes
an N-terminally truncated p53 isoform containing an
initiation codon at amino acid 133, which they named
133p53 (Fig. 2A). Although transcripts encoding a p53
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isoform with an N-terminal truncation of 40 amino acids
(called p44 [Rovinski et al. 1987], Np53 [Courtois et al.
2002], p53/p47 [Yin et al. 2002], and p47 [Ghosh et al.
2004], herein referred to as 40p53 [Bourdon et al. 2005])
had been identified previously as a product of alternative
splicing of intron 2 (Courtois et al. 2002; Ghosh et al.
2004) or altered translation initiation (Yin et al. 2002),
the more extensive truncation in 133p53 makes it dis-
tinct from 40p53 (Fig. 2A). Indeed, 40p53 retains the
second transactivation domain, whereas 133p53 is not
only devoid of both N-terminal transactivation domains,
but is also missing the proline-rich domain implicated in
growth suppression and apoptosis, as well as part of the
DBD.
p53 has dual promoters
Identification of a novel p53 transcript that initiates
within intron 4 prompted Bourdon et al. (2005) to assay
this genomic region for promoter activity. When the pu-
tative intron 4 promoter was cloned upstream of a pro-
moterless luciferase reporter and the intron 4–luciferase
construct was introduced into p53-deficient cells, lucif-
erase activity was induced approximately sixfold relative
to the vector control, which the authors demonstrate is
about as efficient as the polyomavirus promoter. The
ability of this promoter to control initiation from the
same transcriptional start site that they had identified
within intron 4 was not shown. Nonetheless, this dem-
onstrated that this region of intron 4 can indeed function
as a promoter, at least in cultured cells. Although a sec-
ond promoter in p53 had been described previously
within intron 1 (Reisman et al. 1988), this promoter ex-
presses a transcript that is unrelated to p53 (Reisman et
al. 1996). Thus, Bourdon et al. have discovered that p53
contains an internal promoter, making it much more
similar to the dual promoter structure of p63 and p73.
Alternative splicing defines the tail
To identify p53 transcripts generated by this novel p53
promoter, intron 4-specific primers were used in combi-
nation with primers specific for the 3 untranslated re-
gion within exon 11 to amplify cDNAs that contained
both exons 5 and 11. Using total RNA from several nor-
mal human tissues, three distinct p53 transcripts were
generated (Fig. 3). The first transcript encoded full-length
p53, while the other two p53-encoding transcripts had
significant diversity due to an alternative exon located
within intron 9. Thankfully, given the growing number
of different isoforms that are being found for p53 family
members, these transcripts were called  and , to be
consistent with the nomenclature devised for transcripts
that produce p63 and p73. Instead of the normal pattern
of splicing between exons 9 and 10 that occurs to gener-
ate full-length p53, the  and  isoforms are devoid of
amino acids encoded by exon 10, and instead are
equipped with 10 and 15 novel amino acids, respectively,
due to cryptic splice sites located within intron 9 that are
promptly followed by premature stop codons (Fig. 3).
Thus, the  isoform terminates with the amino acids
DQTSFQKENC, whereas the  isoform ends with
MLLDLRWCYFLINSS. Because of this alteration, both 
and  isoforms encode proteins that contain the nuclear
localization signal, but these isoforms lack the oligomer-
ization domain that enables full-length p53 to form func-
tional tetramers (Fig. 2A; Milner et al. 1991). Whether
the unique peptides located at the C terminus of the 
and  isoforms endow these proteins with novel function
is currently unknown.
Transcripts similar to those encoding the  isoform of
p53 were first described in a human T-cell leukemia line
(Chow et al. 1993), and have been characterized more
recently in normal human cells and called p53i9 (Fig. 2B;
Flaman et al. 1996). However, expression at the protein
level had not been reported. In contrast to previous re-
ports describing expression of p53/p53i9 transcripts,
the  isoform that Bourdon et al. (2005) identified had
not been described previously. Although a second alter-
natively spliced p53 transcript called p53as (alternatively
spliced) with a different C terminus had been described
earlier (Wolf et al. 1985; Arai et al. 1986; Han and Kulesz-
Martin 1992; Kulesz-Martin et al. 1994), these tran-
scripts were generated by alternative splicing between
exons 10 and 11, and have been reported to be species-
specific since this product was detected in mouse—but
not in human—cells and tissues (Will et al. 1995;
Laverdiere et al. 2000). Together with previous reports,
this work has provided a fuller appreciation of p53 family
diversity by revealing that nine different p53 proteins
could potentially be expressed (Fig. 2A). Use of both the
P1/P1 and P2 promoters coupled with alternative splic-
ing within intron 9 can generate p53, p53, p53,
133p53, 133p53, and 133p53, as well as 40p53,
40p53, and 40p53 due to alternative splicing within
Figure 1. Identification of the 5 end of p53 transcripts in nor-
mal human tissues. Schematic diagram of the 5 end of the
human p53 gene showing noncoding exons (white) and DBD-
encoding exons (green). (Left) A reverse primer specific for in-
tron 4 amplified transcripts a and b from promoters P1 and P1,
respectively (blue). A reverse primer specific for intron 5 ampli-
fied the transcripts a and b, as well as transcript c generated
from promoter P2 within intron 4.
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intron 2 (Courtois et al. 2002; Ghosh et al. 2004) or al-
ternative initiation of translation (Yin et al. 2002). Given
the possibility of combining mechanisms of diversity,
one has to wonder just how large the p53 isoform family
will grow in the future.
p53 isoform expression at the protein level
To investigate whether these various p53 transcripts can
be translated into p53 proteins, p53-deficient cells were
transiently transfected with expression constructs con-
taining the different p53 cDNAs, and p53 isoform ex-
pression was assessed by Western analysis using p53-
specific antibodies. All p53 transcripts tested produced
p53 proteins: A 45-kDa protein was detected in cells
transfected with p53, or p53, as well as in cells trans-
fected with 40p53; a 35-kDa protein was detected in
cells transfected with 133p53; a 28-kDa protein was
detected in cells transfected with 133p53 and
133p53. This demonstrates that exogenously intro-
duced cDNAs can be expressed in mammalian cells to
generate p53 proteins.
To assess whether endogenous p53 isoforms were ex-
pressed in cultured cells, the DO-12 antibody (specific
for the DBD) (see Fig. 2A) was used to detect p53 proteins
in several transformed cell lines by Western analysis.
The authors found that multiple bands ranging from 35
to 53 kDa were detected in p53-expressing but not in
p53-nonexpressing cells, supporting the notion that mul-
tiple p53 isoforms are expressed in cultured cells. It
should be noted that the discovery of multiple p53 iso-
forms calls for a reevaluation of “p53-null” status in dif-
ferent cell lines. For example, p53 expression was evalu-
ated here using the p53 antibody DO-12 raised against
residues 256–270 of the core DBD (Fig. 2; Vojtesek et al.
1995). Therefore, although this antibody can detect the
nine p53 isoforms described in this study, it does not
detect p53, a p53 isoform that was reported while this
manuscript was in press, which has a deletion within the
DBD (Fig. 2B; Rohaly et al. 2005).
Figure 2. p53 isoforms. (A) p53 isoforms discovered by
Bourdon et al. (2005). Full-length p53 showing transac-
tivation domains 1 and 2 (TA1, TA2), proline-rich do-
main (P), DNA-binding domain (DBD), hinge region (H),
nuclear localization sequence (NLS), and oligomeriza-
tion domain (OD), as well as the relative locations of
the p53 monoclonal antibodies (DO-1, DO-12, 421) that
were used to characterize p53 isoforms in this work.
Other anti-p53 antibodies used in this study that are
not shown include CM1 (raised against full-length p53)
and sheep polyclonal (raised against the first 100 and
the last 60 amino acids of the N and C termini, respec-
tively). The three classes of isoforms have distinct N
termini: full-length p53, 40p53 (generated by alterna-
tive splicing/alternative translation initiation), and
133p53 (generated by transcription from P2 shown in
Fig. 1). Alternative splicing at the C terminus generates
full-length, , and  isoforms for each of the N-terminal
classes. Unique C-terminal residues of the  and  iso-
forms are depicted. The KJC8 antibody was raised
against the unique C terminus of the  isoforms. (B, top)
Schematic diagram of p53 showing transactivation do-
mains 1 and 2 (TA1, TA2), proline-rich domain (P),
DNA-binding domain (DBD), hinge region (H), nuclear
localization sequence (NLS), and oligomerization do-
main (OD). Previously described p53 isoforms are gen-
erated by either alternative splicing or alternative trans-
lation initiation. The N-terminally truncated isoform
designated p44; p53/p47; N-p53; p47 (referred to as
40p53) lacks TA1 (Rovinski et al. 1987; Courtois et al.
2002; Yin et al. 2002; Ghosh et al. 2004). The C-termi-
nally deleted isoform from mouse, p53as (alternatively
spliced), is missing the last 30 amino acids of full-length
p53 (Wolf et al. 1985; Arai et al. 1986; Han and Kulesz-
Martin 1992; Kulesz-Martin et al. 1994), and the C-ter-
minally truncated isoform from humans, p53i9, is miss-
ing the last 60 amino acids of full-length p53 (Chow et
al. 1993; Flaman et al. 1996). p53 has a deletion of 66
amino acids that encompasses part of the core DBD;
this deletion maintains the reading frame (Rohaly et al.
2005). p53 (A) is identical to p53i9 (B) (Chow et al.
1993; Flaman et al. 1996).
p53 isoforms
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Conservation from flies to humans
To investigate whether the complex gene structure of
p53 was evolutionarily conserved, the authors analyzed
the structure of p53 from Drosophila (dp53). By ampli-
fying capped transcripts as they had done for human p53,
they identified two novel exons (A and B) positioned up-
stream of the previously identified dp53 gene (Brodsky et
al. 2000; Jin et al. 2000; Ollmann et al. 2000). This re-
vealed that the promoter that had been characterized in
earlier studies was in reality an internal promoter, an
arrangement analogous to the dual promoter structure of
human p53 (Bourdon et al. 2005), as well as for p63 and
p73. In addition, transcripts resulting from alternative
splicing between exon B and exon 1 (similar to intron 2
alternative splicing that occurs to generate human
40p53 [Courtois et al. 2002; Ghosh et al. 2004]) were
detected. Thus, dp53 expresses three distinct transcripts:
the previously characterized dp53 transcript that en-
codes a 385-amino-acid protein, a novel transcript con-
taining both exons A and B positioned 5 of the dp53
transcript (dp53L) that encodes a 495-amino-acid pro-
tein, and a transcript containing only exons A and B
(dp53n) that encodes a 110-amino-acid protein with only
the transactivation domain. Bourdon et al. (2005) dem-
onstrate that the dp53L transcript encodes a p53 isoform
by showing that a p53-specific antibody can recognize
the in vitro translated protein. A similar analysis was not
possible for the novel dp53n transcript that contains
only exons A and B since the encoded peptide would lack
epitopes recognized by currently available p53 antibod-
ies. Sequence alignment identified a five-residue se-
quence in the newly identified transactivation domain of
dp53L that is evolutionarily conserved in multiple spe-
cies; indeed, this sequence is present not only in p53, but
in p63 and p73, suggesting that it performs a functional
role in modulating the transcriptional ability of p53 fam-
ily members. This analysis also supports the idea that
dp53L is the fly equivalent of full-length p53, TAp63,
and TAp73. Whether or not endogenous dp53L protein
can also be detected in Drosophila tissue was not re-
ported. Future studies will be required to determine
whether p53 isoforms similar to dp53n that contain only
the extreme N terminus are also expressed in mammals.
Which p53 isoforms are expressed in vivo?
To determine whether these distinct p53 transcripts are
being expressed in vivo, an RT–PCR assay that could
discriminate between full-length, , and  isoforms of
both the p53 and the 133p53 classes was developed and
used to screen a panel of normal human tissues. While
p53 transcript was detected in all tissues analyzed,
133p53 was detectable in most, but not all, tissues. 
and  isoforms for both the p53 and 133p53 isoforms
were expressed in a complex pattern. Colon and bone
marrow were the only tissues tested that clearly ex-
pressed all six of the p53 isoforms that were assayed. It
was fortuitous that colon was one of the tissues that
Bourdon et al. (2005) originally selected for identifying
p53 transcripts encoding different isoforms; whether
other tissues had to be screened prior to this “positive”
result was not mentioned. Lung and kidney tissues had
the same pattern of isoform expression for both the p53
and 133p53 classes (lung expressed p53 and 133p53
only, whereas kidney expressed p53/p53 and 133p53/
133p53), demonstrating that both the P1/P1 and the
P2 promoters were active, and that the pattern of C-
terminal splicing was consistent between p53 and
133p53 transcripts in these tissues. Breast tissue was
unique in that it expressed all classes of p53 transcripts
analyzed but did not express detectable levels of the cor-
responding 133p53 transcripts. The take-home message
from this analysis is that the pattern of p53 isoform ex-
pression is complex and appears to be tissue-specific,
making it much more similar to the expression patterns
of p63 and p73 than was realized previously. Since p53
protein levels do not necessarily correlate with p53 ex-
pression at the transcript level (Matlashewski et al. 1986;
Miki et al. 1994), it will be necessary to determine if this
is also the case for different p53 isoforms. Indeed, further
investigation will be required to determine the physi-
ological role(s) of individual p53 isoforms in normal tis-
sues, as well as to investigate whether the tissue-specific
pattern of expression is conserved in other species. Evi-
dence to date suggests that there may be important dif-
ferences between the p53 isoforms expressed in mouse
and human cells; p53as appears to be rodent-specific
(Will et al. 1995; Laverdiere et al. 2000), whereas the
sequences that generate alternative splicing of p53 are
present in primates but not in mouse (Rohaly et al.
2005).
p53 isoforms and cancer
Although p53 status is often an indicator of a patient’s
response to anti-cancer therapies, a clear-cut correlation
between p53 function and treatment response does not
hold for breast cancer. To investigate whether expression
Figure 3. Alternative splicing at the C terminus. (Middle) A
schematic diagram of the 3 region of p53 is shown. Normal
splicing between exons 9 and 10 generates full-length p53 (top),
whereas a novel exon in intron 9 generates the unique  (bottom
left) or  (bottom right) sequence at the C terminus. Asterisks
denote stop codons.
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of various p53 isoforms might be responsible for this
clinical observation, breast tumors were analyzed for ex-
pression of different p53 isoforms. Thirty randomly se-
lected breast tumors were analyzed for expression of p53,
p53, p53, 133p53, 133p53, and 133p53 using
RT–PCR. Whereas normal human breast expresses only
p53, p53, and p53, but not any of the corresponding
133p53 isoforms (see above), transcripts encoding
133p53 isoforms are detected in the majority of breast
tumors. Although all of these tumors express p53 tran-
scripts, albeit at apparently different levels, p53 tran-
scripts were detected in only one-third (10/30) of the
breast tumors, whereas p53, 133p53, and 133p53
were not detected in any of the tumors analyzed. Thus, it
appears that many of the breast tumors tended to lose
expression of p53, while simultaneously gaining ex-
pression of 133p53. The observation that an N-termi-
nally truncated isoform of p53 is up-regulated in tumors
is strikingly reminiscent of the increasing number of re-
ports demonstrating that enhanced p63 expression is a
frequent theme in the vast majority of human cancers
(Crook et al. 2000; Hibi et al. 2000; Yamaguchi et al.
2000; Ito et al. 2001; Quade et al. 2001; Wang et al. 2001,
2002; Choi et al. 2002; Di Como et al. 2002; Hu et al.
2002; Patturajan et al. 2002; Reis-Filho et al. 2002, 2003;
Massion et al. 2003; Pruneri et al. 2005; Tonon et al.
2005). It will be interesting to determine whether tumors
derived from tissues that normally express the N-termi-
nally deleted p53 isoforms, such as lung or colon, retain
expression of these isoforms during the tumorigenic pro-
cess. In addition, it will be important to determine whether
tumors with p53 missense mutations have a particular
pattern of p53 isoform expression. Since only five of the
tumors analyzed had mutant p53 while the majority had
an abnormal pattern of p53 isoform compared to that of
normal breast tissue, the authors speculate that an im-
balance in isoform expression may thwart p53’s tumor
suppressive capabilities, thereby accelerating the tumori-
genic process in the absence of p53 mutation. Whether
certain p53 isoforms can facilitate interactions with p53
proteins containing tumor-derived missense mutations,
as has been shown for both p63 and p73 (Strano et al. 2000,
2002; Gaiddon et al. 2001) awaits further investigation.
Generation of antibodies specific for different p53
isoforms
An important step in elucidating the function of differ-
ent p53 isoforms is the generation of antibodies that
have the ability to discriminate among very similar pro-
teins with distinct epitopes. Indeed, David Lane’s group
(Bourdon et al. 2005) has played a historical part in gen-
erating and characterizing p53 antibodies, making these
reagents available to the p53 community. In keeping
with this tradition, Bourdon et al. (2005) first character-
ized p53-specific antibodies that were already available
to determine which isoforms they recognize. Three dif-
ferent p53-specific antibodies were tested (Fig. 2A): sheep
polyclonal serum specific for epitopes within the first
100 amino acids and the last 60 amino acids of p53
(Midgley et al. 1992); DO-1, a mouse monoclonal anti-
body raised against an epitope located between amino
acids 21–25 (Stephen et al. 1995); and DO-12, a mouse
monoclonal antibody specific for amino acids 256–270 of
the DBD (Vojtesek et al. 1995). Different p53 isoforms
were expressed in p53-deficient cells in culture, and ly-
sates from these cells were screened for p53 proteins by
Western analysis. The anti-p53 sheep polyclonal serum
recognized p53, p53, p53, 40p53, 133p53, as well a
mutant version of 133p53; however, it did not detect
either 133p53 or 133p53, since these isoforms are
lacking both the N and C termini to which this antibody
had been raised. In contrast, DO-12 recognized all six of
these p53 isoforms because the DBD is common to each.
To determine whether p53 isoforms are detectable in
human tumor cell lines, a panel of established lines was
analyzed by Western analysis using the DO-12 antibody.
While the p53-deficient cell lines H1299 and Saos did not
express significant levels of p53, the cell lines SW620,
293, and HT29 expressed multiple p53 proteins robustly.
The p53 antibodies that were currently available were
not specific for individual p53 proteins because they had
been generated against epitopes common to all p53 iso-
forms. To generate reagents that could discriminate
among the different isoforms of p53, Bourdon et al.
(2005) generated a polyclonal antibody (KJC8) against the
peptide sequence DQTSFQKENC that is unique to p53,
40p53, and 133p53 (Fig. 2A). To demonstrate that
this antibody is specific for the  isoforms, p53-deficient
cells were transfected with p53, p53, or 133p53, and
lysates were analyzed by Western analysis. When the
CM1 antibody that had been generated against full-
length p53 was used, both p53 and p53 were detected,
but 133p53 was not. In contrast, KJC8 failed to recog-
nize p53, but specifically detected both p53 and
133p53. When siRNA was used to knock down p53
levels in these cells, the CM1 antibody recognized p53
isoforms that were reduced in cells treated with siRNA
constructs specific for p53. A similar analysis using the
KJC8 antibody determined that siRNA constructs
against p53 efficiently reduced levels of both p53 and
133p53. This analysis demonstrated that the KJC8 an-
tibody is specific for the  isoform subclass. While anti-
bodies specific for the unique epitope at the C terminus
of p53 and 133p53 were not able to be generated to
date, these reagents will be important for further assess-
ing p53 isoforms expression in normal and neoplastic
tissues.
Response to DNA damage
p53 protein is stabilized in response to multiple stimuli
including oncogenes, hypoxia, and DNA damage. To de-
termine whether p53 and 133p53 could be induced
in a manner similar to p53, MCF-7 mammary epithelial
cells (which express endogenous p53) were treated with
the chemotherapeutic drug actinomycin D, and lysates
were subjected to Western analysis. When the DO-1 an-
tibody that recognizes the N terminus of p53 was used,
p53 protein levels were significantly enhanced in re-
p53 isoforms
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sponse to actinomycin D treatment. In contrast, the
KJC8 antibody detected similar levels of p53 and
133p53 protein in both untreated and actinomycin D-
treated cells. This analysis demonstrates that unlike
p53, p53 and 133p53 do not appear to be stabilized in
response to DNA damage. As previous studies demon-
strate that expression of the p53as isoform increases in
response to actinomycin D treatment in normal cells
(Kulesz-Martin et al. 1994), further work will be required
to determine how DNA-damaging agents selectively
trigger the expression of specific p53 isoforms.
Subcellular localization
To examine the subcellular localization of the various
p53 isoforms, H1299 cells were transfected with differ-
ent p53 isoform-encoding constructs, and immunofluo-
rescence was used to identify the subcellular distribu-
tion of p53 proteins. The CM1 antibody detected a
nuclear expression pattern for both p53 and 133p53,
and a nuclear plus a slight cytoplasmic expression pat-
tern for p53 and p53. The KJC8 antibody was used to
determine that 133p53 is expressed in both the
nucleus and the cytoplasm. The DO-12 antibody re-
vealed that the 133p53 isoform is expressed in the
cytoplasm, suggesting that the second alternative exon
within intron 9 can modulate subcellular distribution
even though the nuclear localization sequence is still
present. p53as, with a distinct C-terminal tail, is ex-
pressed in the nucleus (Kulesz-Martin et al. 1994). Al-
though cytoplasmic localization has been shown for the
p53 isoform 40p53 (Ghosh et al. 2004), this protein has
an N-terminal truncation, whereas the cytoplasmic
133p53 has both N- and C-terminal truncations (see
Fig. 2). Deletion of the MDM2-interacting TA1 region in
40p53 results in monoubiquitination and cytoplasmic
localization, as well as a reduction in MDM2-mediated
nuclear export and subsequent degradation of full-length
p53 (Ghosh et al. 2004). Since 133p53 lacks the entire
TA region, it is unlikely to function similarly to 40p53,
which retains the second transactivation domain.
Interaction with full-length p53
To investigate whether the  isoforms can interact with
endogenous full-length p53, the KJC8 antibody was used
for immunoprecipitation, and Western analysis with the
DO-1 antibody specific for the N terminus of p53 was
used to detect p53 isoforms. The KJC8 antibody can ef-
ficiently immunoprecipitate p53 while simultaneously
pulling down endogenous p53 from MCF-7 cells, indicat-
ing that p53 can interact with endogenous p53 in this
cell type. It could not be concluded whether this anti-
body also immunoprecipitates 133p53 and 40p53
since DO-1 was used to detect coimmunoprecipitated
p53, and this antibody is specific for the transactivation
domain and therefore does not detect the  isoforms that
have an N-terminal truncation (see Fig. 2A). Since p53,
40p53, and 133p53 share the epitope to which the
KJC8 antibody was raised, and this antibody was shown
to recognize at least two of the  isoforms, it is likely
that p53, 40p53, and 133p53 are immunoprecipi-
tated in this assay, if these isoforms are expressed in
MCF-7 cells. Although the authors do not discuss the
possibility that N-terminally truncated  isoforms may
also be pulled down in this assay, it is possible that
40p53 and 133p53 also interact with full-length
p53.
Downstream targets
To examine whether p53 (and 40p53 and 133p53?)
can occupy the BAX, p21, and MDM2 promoters, chro-
matin immunopreciptipation (ChIP) was used. As a posi-
tive control, ChIP was performed using the 421 antibody
that had been raised against an epitope between amino
acids 372 and 382 within exon 11, which does not detect
p53 or p53 because these isoforms are missing this
region of the C terminus. The 421 antibody immunopre-
cipitated approximately fivefold more p21 and MDM2
promoter relative to the BAX promoter, indicating that
p53 binds preferentially to the p21 and MDM2 promot-
ers. The anti-p53, -40p53, -133p53 KJC8 antibody,
in contrast, immunoprecipitated approximately sixfold
more p21 and BAX promoter relative to the MDM2 pro-
moter, indicating that  isoforms preferentially bind p21
and BAX promoters. Although it is not certain whether
p53, 40p53, 133p53, or a combination of  iso-
forms are binding chromatin in this assay (see above),
these results demonstrate that at least one of the  iso-
forms can bind the promoters of, and presumably modu-
late the expression of, a subset of p53-responsive genes.
Since these assays were performed in MCF-7 cells
(which express endogenous p53) and p53 can interact
with p53, full-length p53 could be mediating the binding
of p53 to chromatin. In agreement with this possibility,
the authors demonstrate that p53 is unable to transac-
tivate p21 or BAX reporters in p53-deficient cells. Con-
sistent with p53’s ability to occupy the endogenous BAX
and p21 promoters in ChIP experiments, p53 can trans-
activate both the BAX and p21 reporters, although p53’s
effect in both of these assays is lower for the BAX pro-
moter than it is for the p21 promoter. When p53 and
p53 are cotransfected, however, the BAX reporter is
transactivated more efficiently than it is by p53 alone,
and this effect is significantly enhanced by actinomycin
D treatment. Although p53 and p53 have a synergistic
effect on transcriptional activation of the BAX promoter,
the p21 promoter is not further transactivated when p53
and p53 are simultaneously expressed, even though
p53 was shown to occupy this promoter in ChIP experi-
ments. The authors demonstrate that p53 protein levels
are not altered by p53 expression, and thus conclude
that p53 can selectively modulate certain p53-respon-
sive genes at the transcript level.
To examine how p53 and 133p53 affect the bio-
logical function of a well characterized p53-mediated re-
sponse—apoptosis, Bourdon et al. (2005) used FACS
analysis to detect the sub-G1 population in H1299 cells
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expressing p53 or 133p53. Full-length p53 effi-
ciently induces apoptosis, whereas p53 has reduced pro-
apoptotic activity. In contrast, 133p53 is defective in
inducing apoptosis, and can inhibit the pro-apoptotic
capabilities of full-length p53. This dominant negative
effect of N-terminally truncated isoforms on the activity
of full-length isoforms has been demonstrated for both
p63 and p73 (Yang et al. 1998; Pozniak et al. 2000; Stiewe
et al. 2002; Zaika et al. 2002), underscoring that struc-
tural homology between members of the p53 gene family
can be extended to mechanistic similarities as well.
Although the molecular mechanism whereby 133p53
inhibits transactivation of specific p53-modulated target
genes, and how specificity between different promoters
is achieved, warrant future investigation, the functional
features of p53 isoforms described by Bourdon et al.
(2005) are quite different from those of earlier reports of
p53 isoforms. p53i9, which is identical to p53, was pre-
viously reported to be deficient in DNA binding and to
have a transcriptional defect (Flaman et al. 1996),
whereas the Lane group (Bourdon et al. 2005) demon-
strates that not only can  isoforms bind chromatin in
p53-expressing cells, but that p53 isoforms can tran-
scriptionally modulate certain p53-responsive promoters
when p53 is present. Although the reason for disparate
conclusions between these two studies is not clear, it is
likely that the distinct assays used are responsible for
these differences. Indeed, the generation of an antibody
specific for the  isoforms has enhanced the ways in
which the function of these p53 isoforms can be ex-
plored. In contrast, p53as was shown to be constitutively
active for DNA binding (Wu et al. 1994). Although
40p53 binds DNA, it itself is impaired in transactiva-
tion capabilities, and it can even suppress p53-mediated
transcription, thereby dampening p53’s growth suppres-
sive function (Courtois et al. 2002; Yin et al. 2002;
Ghosh et al. 2004). In contrast to the  isoforms of p53,
p53 does not interact with full-length p53 (Rohaly et al.
2005). Although p53 has a substantial deletion that en-
compasses the highly conserved region V of the core
DBD while retaining the reading frame, it is still able to
transactivate a specific subset of p53-responsive genes
involved in cell cycle arrest, but not those involved in
apoptosis. The altered transcriptional ability of p53 me-
diates an ATR–intra S-phase checkpoint that allows for
DNA repair without triggering an apoptotic response
(Rohaly et al. 2005). Thus, the different p53 isoforms
likely have diverse physiological roles.
Closing remarks
This work provides further support for the hypothesis
that p53-related genes arose by triplication of a more
ancestral family member such as the most highly con-
served member, p63. If p53 resulted from triplication of
a more primordial p53-like gene, does the p53 gene in
flies really represent this most ancestral gene? That is, is
Drosophila p53 really more closely related to p63 than it
is to mammalian p53? The work of Bourdon et al. (2005)
provides a new look at similarities between p53 family
members that makes gene nomenclature based on struc-
ture alone less clear. In addition to its insight into evo-
lution of the p53 family of genes, this study has further
implications for the role of p53-related genes in both
cancer and aging; thus it is probable that the p53 family
greatly impacts our future health and longevity. Indeed,
Bourdon et al. (2005) found that tumors that retain wild-
type p53 often express an abnormal balance of p53 iso-
forms. Since N-terminally truncated p53 isoforms can
regulate p53 activity, an alteration in the ratio of differ-
ent p53 isoforms may predispose to cancer, and might
even explain the lack of correlation between p53 muta-
tional status and response to anti-cancer therapies. In
addition, it is likely that an imbalance in p53 isoform
expression could accelerate the aging process. Indeed,
the presence of endogenously expressed N-terminally
truncated p53 isoforms likely explains the fact that al-
though three different mouse models with enhanced p53
activity have been generated (Garcia-Cao et al. 2002;
Tyner et al. 2002; Maier et al. 2004) and these mice are
not susceptible to spontaneous tumors (Garcia-Cao et al.
2002; Tyner et al. 2002), only two of these models de-
velop concomitant accelerated aging phenotypes (Tyner
et al. 2002; Maier et al. 2004). The model that ages nor-
mally was generated by overexpression of the entire p53
locus, presumably causing increased expression of all
p53 isoforms, whereas the models that display acceler-
ated aging phenotypes express enhanced levels of p53
isoforms with N-terminal truncations, suggesting that a
balance between p53 isoforms is essential for tissue ho-
meostasis and longevity. Lastly, this work will likely
shed light on the intricate network involving members
of the p53 family. Indeed, recent work from my labora-
tory demonstrates that p63 deficiency induces cellular
senescence and leads to an accelerated aging phenotype
in vivo, suggesting that longevity is regulated by inter-
actions between p53 and p63 (Keyes et al. 2005). In ad-
dition, although spontaneous tumors have been reported
in one particular p63-deficient mouse model, a distinct
p63-deficient mouse model is not prone to -irradiation-
induced (Perez-Losada et al. 2005), spontaneous, or
chemically induced tumors (W.M. Keyes and A. Mills,
unpubl.), whereas mice overexpressing TAp63 are pre-
disposed to skin cancer in response to carcinogens (M.I.
Koster, S.-L. Lu, X.-J. Wang, and D.R. Roop, in prep).
Intriguingly, the p63 heterozygous mouse model in
which tumors were observed harbors an allele that de-
letes exons encoding a portion of the DBD (Yang et al.
1999; Flores et al. 2005). This deletion maintains the
reading frame, a situation that could generate a p63 iso-
form that is functionally similar to p53 (Rohaly et al.
2005). Future experiments will be needed to gain further
insight into how the array of p53 isoforms described by
the Lane group (Bourdon et al. 2005) modulate the func-
tion(s) of p53-related proteins p63 and p73. This will pro-
vide a better understanding of how the p53 family of
genes evolved, and will undoubtedly impact the fields of
both cancer and aging. Thus, as Alex Haley wrote, “in
every conceivable manner, the [p53] family is link to our
past, bridge to our future.”
p53 isoforms
GENES & DEVELOPMENT 2097
Acknowledgments
I thank Bill Tansey for helpful discussions, and Cristian Papazo-
glu for critical reading of the manuscript.
References
Arai, N., Nomura, D., Yokota, K., Wolf, D., Brill, E., Shohat, O.,
and Rotter, V. 1986. Immunologically distinct p53 mol-
ecules generated by alternative splicing. Mol. Cell. Biol.
6: 3232–3239.
Bienz-Tadmor, B., Zakut-Houri, R., Libresco, S., Givol, D., and
Oren, M. 1985. The 5 region of the p53 gene: Evolutionary
conservation and evidence for a negative regulatory element.
EMBO J. 4: 3209–3213.
Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G.,
Diot, A., Xirodimas, D.P., Saville, M.K., and Lane, D.P. 2005.
p53 isoforms can regulate p53 transcriptional acivity. Genes
& Dev. (this issue).
Brodsky, M.H., Nordstrom, W., Tsang, G., Kwan, E., Rubin,
G.M., and Abrams, J.M. 2000. Drosophila p53 binds a dam-
age response element at the reaper locus. Cell 101: 103–113.
Choi, H.R., Batsakis, J.G., Zhan, F., Sturgis, E., Luna, M.A., and
El-Naggar, A.K. 2002. Differential expression of p53 gene
family members p63 and p73 in head and neck squamous
tumorigenesis. Hum. Pathol. 33: 158–164.
Chow, V.T., Quek, H.H., and Tock, E.P. 1993. Alternative splic-
ing of the p53 tumor suppressor gene in the Molt-4 T-lym-
phoblastic leukemia cell line. Cancer Lett. 73: 141–148.
Courtois, S., Verhaegh, G., North, S., Luciani, M.G., Lassus, P.,
Hibner, U., Oren, M., and Hainaut, P. 2002. N-p53, a natu-
ral isoform of p53 lacking the first transactivation domain,
counteracts growth suppression by wild-type p53. Oncogene
21: 6722–6728.
Crook, T., Nicholls, J.M., Brooks, L., O’Nions, J., and Allday,
M.J. 2000. High level expression of N-p63: A mechanism
for the inactivation of p53 in undifferentiated nasopharyn-
geal carcinoma (NPC)? Oncogene 19: 3439–3444.
Di Como, C.J., Urist, M.J., Babayan, I., Drobnjak, M., Hedvat,
C.V., Teruya-Feldstein, J., Pohar, K., Hoos, A., and Cordon-
Cardo, C. 2002. p63 expression profiles in human normal
and tumor tissues. Clin. Cancer Res. 8: 494–501.
Flaman, J.M., Waridel, F., Estreicher, A., Vannier, A., Limacher,
J.M., Gilbert, D., Iggo, R., and Frebourg, T. 1996. The human
tumour suppressor gene p53 is alternatively spliced in nor-
mal cells. Oncogene 12: 813–818.
Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J., Bronson, R.,
Crowley, D., Yang, A., McKeon, F., and Jacks, T. 2005. Tu-
mor predisposition in mice mutant for p63 and p73: Evi-
dence for broader tumor suppressor functions for the p53
family. Cancer Cell 7: 363–373.
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., and Prives, C.
2001. A subset of tumor-derived mutant forms of p53 down-
regulate p63 and p73 through a direct interaction with the
p53 core domain. Mol. Cell. Biol. 21: 1874–1887.
Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado,
L.M., Klatt, P., Flores, J.M., Weill, J.C., Blasco, M.A., and
Serrano, M. 2002. ‘Super p53’ mice exhibit enhanced DNA
damage response, are tumor resistant and age normally.
EMBO J. 21: 6225–6235.
Ghosh, A., Stewart, D., and Matlashewski, G. 2004. Regulation
of human p53 activity and cell localization by alternative
splicing. Mol. Cell. Biol. 24: 7987–7997.
Han, K.A. and Kulesz-Martin, M.F. 1992. Alternatively spliced
p53 RNA in transformed and normal cells of different tissue
types. Nucleic Acids Res. 20: 1979–1981.
Hibi, K., Trink, B., Patturajan, M., Westra, W.H., Caballero,
O.L., Hill, D.E., Ratovitski, E.A., Jen, J., and Sidransky, D.
2000. AIS is an oncogene amplified in squamous cell carci-
noma. Proc. Natl. Acad. Sci. 97: 5462–5467.
Hu, H., Xia, S.H., Li, A.D., Xu, X., Cai, Y., Han, Y.L., Wei, F.,
Chen, B.S., Huang, X.P., Han, Y.S., et al. 2002. Elevated ex-
pression of p63 protein in human esophageal squamous cell
carcinomas. Int. J. Cancer 102: 580–583.
Ito, Y., Takeda, T., Wakasa, K., Tsujimoto, M., Sakon, M., and
Matsuura, N. 2001. Expression of p73 and p63 proteins in
pancreatic adenocarcinoma: p73 overexpression is inversely
correlated with biological aggressiveness. Int. J. Mol. Med.
8: 67–71.
Jin, S., Martinek, S., Joo, W.S., Wortman, J.R., Mirkovic, N., Sali,
A., Yandell, M.D., Pavletich, N.P., Young, M.W., and Levine,
A.J. 2000. Identification and characterization of a p53 homo-
logue in Drosophila melanogaster. Proc. Natl. Acad. Sci.
97: 7301–7306.
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C.,
Valent, A., Minty, A., Chalon, P., Lelias, J.M., Dumont, X., et
al. 1997. Monoallelically expressed gene related to p53 at
1p36, a region frequently deleted in neuroblastoma and other
human cancers. Cell 90: 809–819.
Keyes, W.M., Wu, Y., Vogel, H., Guo, X., Lowe, S.W., and Mills,
A.A. p63 deficiency activates a program of cellular senes-
cence and leads to accelerated aging. Genes & Dev.
19: 1986–1999.
Kulesz-Martin, M.F., Lisafeld, B., Huang, H., Kisiel, N.D., and
Lee, L. 1994. Endogenous p53 protein generated from wild-
type alternatively spliced p53 RNA in mouse epidermal
cells. Mol. Cell. Biol. 14: 1698–1708.
Lamb, P. and Crawford, L. 1986. Characterization of the human
p53 gene. Mol. Cell. Biol. 6: 1379–1385.
Lane, D.P. and Crawford, L.V. 1979. T antigen is bound to a host
protein in SV40-transformed cells. Nature 278: 261–263.
Laverdiere, M., Beaudoin, J., and Lavigueur, A. 2000. Species-
specific regulation of alternative splicing in the C-terminal
region of the p53 tumor suppressor gene. Nucleic Acids Res.
28: 1489–1497.
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K.,
Guise, T., Sutherland, A., Thorner, M., and Scrable, H. 2004.
Modulation of mammalian life span by the short isoform of
p53. Genes & Dev. 18: 306–319.
Massion, P.P., Taflan, P.M., Jamshedur Rahman, S.M., Yildiz,
P., Shyr, Y., Edgerton, M.E., Westfall, M.D., Roberts, J.R.,
Pietenpol, J.A., Carbone, D.P., et al. 2003. Significance of p63
amplification and overexpression in lung cancer develop-
ment and prognosis. Cancer Res. 63: 7113–7121.
Matlashewski, G., Banks, L., Pim, D., and Crawford, L. 1986.
Analysis of human p53 proteins and mRNA levels in normal
and transformed cells. Eur. J. Biochem. 154: 665–672.
Midgley, C.A., Fisher, C.J., Bartek, J., Vojtesek, B., Lane, D., and
Barnes, D.M. 1992. Analysis of p53 expression in human
tumours: An antibody raised against human p53 expressed in
Escherichia coli. J. Cell Sci. 101 (Pt 1): 183–189.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harsh-
man, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M.,
Ding, W., et al. 1994. A strong candidate for the breast and ovar-
ian cancer susceptibility gene BRCA1. Science 266: 66–71.
Milner, J., Medcalf, E.A., and Cook, A.C. 1991. Tumor suppres-
sor p53: Analysis of wild-type and mutant p53 complexes.
Mol. Cell. Biol. 11: 12–19.
Mullis, K.B. and Faloona, F.A. 1987. Specific synthesis of DNA
in vitro via a polymerase-catalyzed chain reaction. Methods
Enzymol. 155: 335–350.
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., and Erlich,
Mills
2098 GENES & DEVELOPMENT
H. 1986. Specific enzymatic amplification of DNA in vitro:
The polymerase chain reaction. Cold Spring Harb. Symp.
Quant. Biol. 51 Pt 1: 263–273.
Ollmann, M., Young, L.M., Di Como, C.J., Karim, F., Belvin, M.,
Robertson, S., Whittaker, K., Demsky, M., Fisher, W.W.,
Buchman, A., et al. 2000. Drosophila p53 is a structural and
functional homolog of the tumor suppressor p53. Cell
101: 91–101.
Patturajan, M., Nomoto, S., Sommer, M., Fomenkov, A., Hibi,
K., Zangen, R., Poliak, N., Califano, J., Trink, B., Ratovitski,
E., et al. 2002. Np63 induces -catenin nuclear accumula-
tion and signaling. Cancer Cell 1: 369–379.
Perez-Losada, J., Wu, D., Delrosario, R., Balmain, A., and Mao,
J.H. 2005. p63 and p73 do not contribute to p53-mediated
lymphoma suppressor activity in vivo. Oncogene (in press).
[Epub June 20.]
Pozniak, C.D., Radinovic, S., Yang, A., McKeon, F., Kaplan,
D.R., and Miller, F.D. 2000. An anti-apoptotic role for the
p53 family member, p73, during developmental neuron
death [see comments]. Science 289: 304–306.
Pruneri, G., Fabris, S., Dell’Orto, P., Biasi, M.O., Valentini, S.,
Del Curto, B., Laszlo, D., Cattaneo, L., Fasani, R., Rossini, L.,
et al. 2005. The transactivating isoforms of p63 are overex-
pressed in high-grade follicular lymphomas independent of
the occurrence of p63 gene amplification. J. Pathol.
206: 337–345.
Quade, B.J., Yang, A., Wang, Y., Sun, D., Park, J., Sheets, E.E.,
Cviko, A., Federschneider, J.M., Peters, R., McKeon, F.D., et
al. 2001. Expression of the p53 homologue p63 in early cer-
vical neoplasia. Gynecol. Oncol. 80: 24–29.
Reis-Filho, J.S., Torio, B., Albergaria, A., and Schmitt, F.C. 2002.
p63 expression in normal skin and usual cutaneous carcino-
mas. J. Cutan. Pathol. 29: 517–523.
Reis-Filho, J.S., Simpson, P.T., Martins, A., Preto, A., Gartner,
F., and Schmitt, F.C. 2003. Distribution of p63, cytokeratins
5/6 and cytokeratin 14 in 51 normal and 400 neoplastic hu-
man tissue samples using TARP-4 multi-tumor tissue mi-
croarray. Virchows Arch. 443: 122–132.
Reisman, D., Greenberg, M., and Rotter, V. 1988. Human p53
oncogene contains one promoter upstream of exon 1 and a
second, stronger promoter within intron 1. Proc. Natl. Acad.
Sci. 85: 5146–5150.
Reisman, D., Balint, E., Loging, W.T., Rotter, V., and Almon, E.
1996. A novel transcript encoded within the 10-kb first in-
tron of the human p53 tumor suppressor gene (D17S2179E)
is induced during differentiation of myeloid leukemia cells.
Genomics 38: 364–370.
Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A.M., Heuke-
shoven, J., Deppert, W., and Dornreiter, I. 2005. A novel
human p53 isoform is an essential element of the ATR–
intra-S phase checkpoint. Cell 122: 21–32.
Rovinski, B., Munroe, D., Peacock, J., Mowat, M., Bernstein, A.,
and Benchimol, S. 1987. Deletion of 5-coding sequences of
the cellular p53 gene in mouse erythroleukemia: A novel
mechanism of oncogene regulation. Mol. Cell. Biol. 7: 847–853.
Schmale, H. and Bamberger, C. 1997. A novel protein with
strong homology to the tumor suppressor p53. Oncogene
15: 1363–1367.
Stephen, C.W., Helminen, P., and Lane, D.P. 1995. Characteri-
sation of epitopes on human p53 using phage-displayed pep-
tide libraries: Insights into antibody–peptide interactions. J.
Mol. Biol. 248: 58–78.
Stiewe, T., Theseling, C.C., and Putzer, B.M. 2002. Transacti-
vation-deficient TA-p73 inhibits p53 by direct competition
for DNA binding: Implications for tumorigenesis. J. Biol.
Chem. 277: 14177–14185.
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y.,
Castagnoli, L., Levine, A.J., Sacchi, A., Cesareni, G., Oren,
M., et al. 2000. Physical and functional interaction between
p53 mutants and different isoforms of p73. J. Biol. Chem.
275: 29503–29512.
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti,
O., Baccarini, A., Del Sal, G., Levrero, M., Sacchi, A., Oren,
M., et al. 2002. Physical interaction with human tumor-de-
rived p53 mutants inhibits p63 activities. J. Biol. Chem.
277: 18817–18826.
Tonon, G., Wong, K.K., Maulik, G., Brennan, C., Feng, B.,
Zhang, Y., Khatry, D.B., Protopopov, A., You, M.J., Aguirre,
A.J., et al. 2005. High-resolution genomic profiles of human
lung cancer. Proc. Natl. Acad. Sci. 102: 9625–9630.
Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious,
N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C.,
et al. 2002. p53 mutant mice that display early ageing-asso-
ciated phenotypes. Nature 415: 45–53.
Vojtesek, B., Dolezalova, H., Lauerova, L., Svitakova, M., Hav-
lis, P., Kovarik, J., Midgley, C.A., and Lane, D.P. 1995. Con-
formational changes in p53 analysed using new antibodies to
the core DNA binding domain of the protein. Oncogene
10: 389–393.
Wang, T.Y., Chen, B.F., Yang, Y.C., Chen, H., Wang, Y., Cviko,
A., Quade, B.J., Sun, D., Yang, A., McKeon, F.D., et al. 2001.
Histologic and immunophenotypic classification of cervical
carcinomas by expression of the p53 homologue p63: A study
of 250 cases. Hum. Pathol. 32: 479–486.
Wang, B.Y., Gil, J., Kaufman, D., Gan, L., Kohtz, D.S., and Burst-
ein, D.E. 2002. P63 in pulmonary epithelium, pulmonary
squamous neoplasms, and other pulmonary tumors. Hum.
Pathol. 33: 921–926.
Will, K., Warnecke, G., Bergmann, S., and Deppert, W. 1995.
Species- and tissue-specific expression of the C-terminal al-
ternatively spliced form of the tumor suppressor p53.
Nucleic Acids Res. 23: 4023–4028.
Wolf, D., Harris, N., Goldfinger, N., and Rotter, V. 1985. Isola-
tion of a full-length mouse cDNA clone coding for an im-
munologically distinct p53 molecule. Mol. Cell. Biol.
5: 127–132.
Wu, Y., Liu, Y., Lee, L., Miner, Z., and Kulesz-Martin, M. 1994.
Wild-type alternatively spliced p53: Binding to DNA and
interaction with the major p53 protein in vitro and in cells.
EMBO J. 13: 4823–4830.
Yamaguchi, K., Wu, L., Caballero, O.L., Hibi, K., Trink, B.,
Resto, V., Cairns, P., Okami, K., Koch, W.M., Sidransky, D.,
et al. 2000. Frequent gain of the p40/p51/p63 gene locus in
primary head and neck squamous cell carcinoma. Int. J. Can-
cer 86: 684–689.
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M.D.,
Dotsch, V., Andrews, N.C., Caput, D., and McKeon, F. 1998.
p63, a p53 homolog at 3q27-29, encodes multiple products
with transactivating, death-inducing, and dominant-nega-
tive activities. Mol. Cell 2: 305–316.
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bron-
son, R.T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al.
1999. p63 is essential for regenerative proliferation in limb,
craniofacial and epithelial development. Nature 398: 714–718.
Yin, Y., Stephen, C.W., Luciani, M.G., and Fahraeus, R. 2002.
p53 stability and activity is regulated by Mdm2-mediated
induction of alternative p53 translation products. Nat. Cell
Biol. 4: 462–467.
Zaika, A.I., Slade, N., Erster, S.H., Sansome, C., Joseph, T.W.,
Pearl, M., Chalas, E., and Moll, U.M. 2002. Np73, a domi-
nant-negative inhibitor of wild-type p53 and TAp73, is up-
regulated in human tumors. J. Exp. Med. 196: 765–780.
p53 isoforms
GENES & DEVELOPMENT 2099
